Bifemelane

	WikiDoc Resources for Bifemelane
Articles
Most recent articles on Bifemelane Most cited articles on Bifemelane Review articles on Bifemelane Articles on Bifemelane in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bifemelane Images of Bifemelane Photos of Bifemelane Podcasts & MP3s on Bifemelane Videos on Bifemelane
Evidence Based Medicine
Cochrane Collaboration on Bifemelane Bandolier on Bifemelane TRIP on Bifemelane
Clinical Trials
Ongoing Trials on Bifemelane at Clinical Trials.gov Trial results on Bifemelane Clinical Trials on Bifemelane at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bifemelane NICE Guidance on Bifemelane NHS PRODIGY Guidance FDA on Bifemelane CDC on Bifemelane
Books
Books on Bifemelane
News
Bifemelane in the news Be alerted to news on Bifemelane News trends on Bifemelane
Commentary
Blogs on Bifemelane
Definitions
Definitions of Bifemelane
Patient Resources / Community
Patient resources on Bifemelane Discussion groups on Bifemelane Patient Handouts on Bifemelane Directions to Hospitals Treating Bifemelane Risk calculators and risk factors for Bifemelane
Healthcare Provider Resources
Symptoms of Bifemelane Causes & Risk Factors for Bifemelane Diagnostic studies for Bifemelane Treatment of Bifemelane
Continuing Medical Education (CME)
CME Programs on Bifemelane
International
Bifemelane en Espanol Bifemelane en Francais
Business
Bifemelane in the Marketplace Patents on Bifemelane
Experimental / Informatics
List of terms related to Bifemelane

Bifemelane
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N06AX08 (WHO) ;
Identifiers
	IUPAC name N-methyl-4-[2-(phenylmethyl)phenoxy]butan-1-amine;
CAS Number	90293-01-9 ;
PubChem CID	2377;
ChemSpider	2286 ;
UNII	Z4501GN13G;
ChEMBL	ChEMBL1192517 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H23NO
Molar mass	269.381 g/mol
3D model (JSmol)	Interactive image;
	SMILES O(c1ccccc1Cc2ccccc2)CCCCNC;
	InChI InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3 ; Key:QSQQPMHPCBLLGX-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bifemelane (Alnert, Celeport) is a pharmaceutical drug used in the treatment of senile dementia in Japan.^[1] It has nootropic, neuroprotective, and antidepressant effects, and acts through the cholinergic system in the brain.^[2]^[3]^[4] Bifemelane is also useful for the treatment of glaucoma.^[5]

↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265. ISBN 0-412-46630-9.
↑ Kondo, Y; Ogawa, N; Asanuma, M; Matsuura, K; Nishibayashi, K; Iwata, E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience research. 24 (4): 409–14. doi:10.1016/0168-0102(95)01017-3. PMID 8861111.
↑ Egashira, T; Takayama, F; Yamanaka, Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese journal of pharmacology. 72 (1): 57–65. doi:10.1254/jjp.72.57. PMID 8902600.
↑ Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". Pharmacology & Toxicology. 72 (6): 394–7. doi:10.1111/j.1600-0773.1993.tb01351.x. PMID 8361950.
↑ Shigemitsu, T; Majima, Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical therapeutics. 18 (1): 106–13. doi:10.1016/S0149-2918(96)80183-4. PMID 8851457.